{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fpoliticos-pulse-check.simplecast.com%2Fepisodes%2Fcompetition-is-coming-for-a-top-drug-QjowgCZS","width":444,"version":"1.0","type":"rich","title":"Competition is coming for a top drug","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/4da913b0-f9d2-4c36-aafd-0cefba14ffbc/53dd2434-9a18-4ec1-b716-3a0d79d20428/politico-pulse-check-audio-audio.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/ea1bcee9-3bca-4821-9238-2e8ecd23d4e0\" height=\"200\" width=\"100%\" title=\"Competition is coming for a top drug\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Today in our Pulse Check podcast, Lauren Gardner talks with Megan Messerly about the introduction of biosimilars next year to compete with Humira, the anti-inflammatory used to treat arthritis that has been the best-selling drug in America. Competition could reduce prices for consumers, but that’s not certain. Lauren explains how it could play out. "}